Anti-Canine parvovirus Monoclonal antibody, Clone 5G8

Canine Parvovirus (CPV) is a DNA virus of the Parvovirus family and genus Parvovirus. CPV is an octopus-shaped, icosahedral, single-stranded DNA virus, which is 18–26 nm in diameter. It encodes two different proteins, both non-structural (NS1 and NS2) and structural (VP1 and VP2). It is roughly 5 kb length. The biggest protein on the capsid, VP2, makes up over 90% of the capsid and is the antigen that activates the host immune system. NS1 is the component that regulates viral replication. CPV's genetic variation is largely a result of VP2 gene mutations. Three main antigenic strains of CPV exist, each one being distinct from the others in pathogenicity and antigenicity: CPV-2a, CPV-2b, and CPV-2c. They have discovered that these variations affect both how the virus mutates and whether vaccines work, and that CPV genetic evolution therefore requires close observation. CPV generally strikes canids, especially unvaccinated puppies. The virus propagates through the stool-oral path and primarily attacks intestinal epithelial cells, lymphoid tissue and bone marrow cells, inflicting severe tissue destruction. Gingival – the most common, characterized by excessive vomiting, severe diarrhea (usually bloody), fever, weakness, and hunger. Sometimes, at the most serious level, death is a consequence of dehydration and electrolyte disturbances. Myocarditis is more common in unvaccinated puppies, and it can cause myocarditis and sudden death. Further, in the laboratory CPV infection can inhibit lymphocyte proliferation and apoptosis, reducing the host immune system. This process can accelerate disease development and facilitate secondary infection.

Figure 1. General Structure of Canine Parvovirus, and 1B. Structure of Coronavirus. Canine Parvovirus Is About a Quarter the Size of Coronavirus. (Source: Sykes JE, 2014)

Rapid and accurate laboratory diagnosis is crucial for preventing and controlling CPV infections. Common detection methods include antigen testing and molecular biological techniques. The enzyme-linked immunosorbent assay (ELISA) and colloidal gold strip test for CPV antigen determination is quick and easy to use and suitable for clinical diagnosis; however, its specificity and sensitivity are subject to sample quality considerations. PCR is a high-sensitivity, high-specificity polymerase chain reaction (PCR) technique that is widely employed to identify viral nucleic acid in the samples with low viral load. Viral isolation and serology (assimilating antibody detection, etc.) are also relevant in research. There are no CPV antivirals available currently, and treatment is primarily supportive, treating symptoms and secondary infections. We have fluids to control the dehydration and electrolytes, antibiotics to prevent the subsequent bacterial infection, and antiemetics and antidiarrhea medication to soothe the digestive symptoms. Some research indicates that early exposure to high-titer anti-CPV monoclonal antibodies or hyperimmune serum will significantly reduce death infected dogs. Efforts in the field of antivirals have been making headway. Nucleoside analogs, such as benzimidazoles, are known to stop CPV replication. Other technologies such as RNA interference (RNAi) and gene editing (CRISPR-Cas9) could one day be used to find individualized therapies for CPV.

Figure 2. Global Distribution of CPV-2a, 2b, and 2c. (Source: Zhou P, et al., 2017)

CPV infection is preventable and eliminated by vaccination. The majority of vaccines available today are recombinant live vaccines that generate persistent immune memory and remain the most popular vaccine in clinical use. Yet CPV's rapid mutation poses a challenge to the cross-protection of current vaccines, particularly against CPV-2c (which needs further confirmation). Researchers would need to seek to make broader-spectrum vaccines (recombinant protein vaccines, mRNA vaccines) to address the virus's antigenic variability. In addition, adherence to vaccination schedules — particularly during the puppy years (at 6-8 weeks, followed by injections every 3-4 weeks until 16 weeks) and every year with booster shots for adults — is essential to immune protection. Research has established that an effective vaccine strategy delivers protection up to 98%. But the development of antigenic variants has put the protective potential of current vaccines at risk, and as CPV-2c has expanded in some parts of the world, we've had to keep our vaccines up-to-date. Prevention should include environmental disinfection and infection control in addition to vaccination. CPV is highly stable in the environment and can survive for months in feces, soil, and contaminated materials. Sodium hypochlorite solution is considered the most effective disinfectant, making regular treatment of kennels and feeding equipment essential. Preventing unvaccinated dogs from entering high-risk environments and maintaining good management practices can significantly reduce the risk of infection. As research into viral genomics and immunology advances, CPV prevention and control methods will continue to improve. Future research directions include the development of broad-spectrum vaccines for all variants, the creation of specific antiviral drugs, and the exploration of more efficient immunotherapy strategies. Furthermore, global molecular epidemiological surveillance to track the virus's evolutionary pathways and antigenic changes will help refine control strategies. Even with vaccines and treatments in place, CPV is a very transmittable and deadly pathogen, which remains a health hazard for canid species, given its transmissibility and adaptation. Deep-dive investigations of the virus's molecular structure and immunological nature will not only be used as a basis for vaccines and treatments, but will find broader applications in animal medicine and biotechnology.

Figure 3. PCR Technique: Rapid, Sensitive, and Accurate, Widely Used for Diagnosing Canine Parvovirus Infection. (Source: Nandi S, Kumar M, 2010)

Canine Parvovirus Monoclonal Antibody
Anti-CPV Monoclonal Antibody Monoclonal
Antibody for Canine Parvovirus
Dog Parvovirus Monoclonal Antibody